Podcasts
Listen to the latest hemonc news from international experts
The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 highlights in AL amyloidosis: risk stratification, bispecific antibodies, CAR-T, & MRD
This VJHemOnc podcast highlights key AL amyloidosis updates from ASH 2025. Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, discusses a newly validated staging system defining ultra-high-risk disease in the daratumumab era.
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, presents Phase II AQUARIUS data (NCT05250973) on daratumumab-VCd dosing and Phase I etentamig results (NCT06158854) in relapsed or refractory AL amyloidosis. Heather Landau, MD, Memorial Sloan Kettering Cancer Center, New York, NY, reviews early NEXICART-2 findings (NCT06097832) with BCMA-directed CAR T-cell therapy, Andrew Staron, MD, Boston Medical Center, Boston, MA, discusses sustained MRD negativity, and Matthew Rees, MD, St. Vincent’s Hospital, Melbourne, Australia, shares real-world BCMA-directed CAR T-cell and bispecific data.
Date: 6th February 2026
